Effect of high-dose valsartan on inflammatory and lipid parameters in patients with Type 2 diabetes and hypertension

Diabetes Research and Clinical Practice

Volumn 89, Issue 3, 2010, Pages 209-215

  Kintscher, Ulrich ^a   Marx, Nikolaus ^b   Martus, Peter ^a   Stoppelhaar, Martina ^a   Schimkus, Julia ^a   Schneider, Anna ^a   Walcher, Daniel ^c   Kümmel, Andreas ^c   Winkler, Robin ^a   Kappert, Kai ^a   Dörffel, Yvonne ^a   Scholze, Jürgen ^a   Unger, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

Angiotensin receptor blocker; Cholesterol; Diabetes mellitus; Hypertension; Inflammation

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

ADD ON THERAPY; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT DURATION;

EID: 77955431539     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.04.018     Document Type: Article

References (21)

1. de Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 2000, 52:415-472.
2. Schmieder R.E., Hilgers K.F., Schlaich M.P., Schmidt B.M. Renin-angiotensin system and cardiovascular risk. Lancet 2007, 369:1208-1219.
3. Kintscher U., Foryst-Ludwig A., Unger T. Inhibiting angiotensin type 1 receptors as a target for diabetes. Expert Opin. Ther. Targets 2008, 12:1257-1263.
4. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
5. Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766.
6. Scheen A.J. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004, 64:2537-2565.
7. Tershakovec A.M., Keane W.F., Zhang Z., Lyle P.A., Appel G.B., McGill J.B., et al. Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study. Diabetes Care 2008, 31:445-447.
8. Weber M.A., Julius S., Kjeldsen S.E., Brunner H.R., Ekman S., Hansson L., et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004, 363:2049-2051.
9. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J. Clin. Invest. 2006, 116:1793-1801.
10. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42-47.
11. Fleischman A., Shoelson S.E., Bernier R., Goldfine A.B. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008, 31:289-294.
12. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z.W., Karin M., et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293:1673-1677.
13. Brasier A.R., Recinos A., Eledrisi M.S. Vascular inflammation and the renin-angiotensin system. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1257-1266.
14. Fliser D., Buchholz K., Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004, 110:1103-1107.
15. Sola S., Mir M.Q., Cheema F.A., Khan-Merchant N., Menon R.G., Parthasarathy S., et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005, 111:343-348.
16. Gaudio G., Guasti L., Schizzarotto A., Simoni C., Crespi C., Cimpanelli M., et al. Changes in plasma lipids during renin-angiotensin system blockade by combination therapy (enalapril plus valsartan) in patients with diabetes and hypertension. J. Cardiovasc. Pharmacol. 2005, 45:362-366.
17. Hanefeld M., Abletshauser C. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J. Int. Med. Res. 2001, 29:270-279.
18. Hirano T., Ran J., Adachi M. Opposing actions of angiotensin II type 1 and 2 receptors on plasma cholesterol levels in rats. J. Hypertens. 2006, 24:103-108.
19. Fogari R., Derosa G., Zoppi A., Rinaldi A., Lazzari P., Fogari E., et al. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens. Res. 2005, 28:209-214.
20. Lee J.M., Kim J.H., Son H.S., Hong E.G., Yu J.M., Han K.A., et al. Valsartan Increases Circulating Adiponectin Levels without Changing HOMA-IR in Patients with Type 2 Diabetes Mellitus and Hypertension. J. Int. Med. Res. 2010, 38:234-241.
21. Erren M., Reinecke H., Junker R., Fobker M., Schulte H., Schurek J.O., et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2355-2363.